Chinese vaccine developers have been slow compared with their western peers in releasing efficacy data on their shots. The trial produced efficacy data that differed from tests carried out in other countries, Gorinchteyn said, without elaborating. Sinovac’s shot is potentially more suited to developing countries because it can be kept at normal refrigerator temperatures. Neither CNBG nor Sinopharm has commented on the UAE announcement, nor released interim efficacy data directly. The Sinovac vaccine has been at the center of a political dispute between Doria and President Jair Bolsonaro, who says a vaccine from China can’t be trusted.

Source: Hindustan Times December 24, 2020 07:41 UTC